Smoking Cessation Aids Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 32.60 Billion |
| Market Size (2029) | USD 55.84 Billion |
| CAGR (2024 - 2029) | 11.37 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Smoking Cessation Aids Market Analysis
The Smoking Cessation Aids Market size is estimated at USD 32.60 billion in 2024, and is expected to reach USD 55.84 billion by 2029, growing at a CAGR of 11.37% during the forecast period (2024-2029).
Factors such as a large population addicted to smoking, growing awareness of the hazards of smoking, and banning advertisements of tobacco products are expected to boost market growth over the forecast period.
Increasing government initiatives toward organizing various tobacco and smoking cessation campaigns raise awareness among the population regarding their harmful effects on the body. It is anticipated to fuel the adoption of smoking cessation devices and products among users. For instance, in May 2022, K Sudhakar, the Health Minister of Karnataka, India, launched the 'IndiaVsTobacco' campaign. This initiative featured QR code-enabled billboards and posters aimed at mobilizing youth, parents, and institutions to combat tobacco usage. The interactive billboards were designed to initiate conversations about the dangers of secondhand smoke and the broader health risks associated with tobacco. Campaigns like these not only raise awareness about smoking hazards and treatments but also catalyze market growth.
The escalating use of tobacco, particularly in the form of cigarettes, has contributed to a growing global healthcare burden. Data from the Centers for Disease Control and Prevention (CDC) in November 2023 revealed that 6.6% of middle school students and 12.6% of high school students used tobacco products. Therefore, with the high number of smokers, the usage of nicotine replacement therapy and smoking cessation products is expected to increase, which is expected to boost market growth over the forecast period.
Furthermore, the rising focus by companies on developing and launching smoking cessation drugs and devices in the market is expected to increase their adoption among users, which is anticipated to augment market growth over the forecast period. For instance, in February 2022, betapharm Arzneimittel GmbH launched the first generic nicotine chewing gum, Nicotine Beta, in the German market. It is a generic product underlining the advantages of NRT (nicotine replacement therapy).
Moreover, the rising number of clinical studies conducted by key players to develop novel drugs for smoking cessation is anticipated to augment market growth over the forecast period. For instance, in May 2024, Achieve Life Sciences Inc. released the findings of its ORCA-V1 trial in the Journal of the American Medical Association (JAMA), Internal Medicine. The study, conducted on 160 non-smoking adults who were e-cigarette or nicotine vape users attempting to quit, evaluated the effectiveness and safety of a 3 mg dose of cytisinicline given three times a day for 12 weeks, as opposed to a placebo.
The market studied is expected to grow over the forecast period due to factors such as growing awareness campaigns, increasing use of cigarettes, and product launches by market players. However, the adverse effects of drugs are likely to impede the market's growth over the forecast period.
Smoking Cessation Aids Market Trends
Electronic Cigarettes Segment Expected to Witness Significant Growth Over the Forecast Period
Electronic cigarettes (e-cigarettes), also known as vaping devices, are electronic devices used to inhale an aerosol that typically contains nicotine, flavors, and other substances. Cartridges and disposables are the two primary types of e-cigarettes. Cartridges are reusable and designed for multiple uses. The pre-filled cartridge is often changed when it is empty. Disposables are discarded after they run out of juice or charge because they cannot be recharged or refilled.
The e-cigarette segment is expected to witness significant growth in the smoking cessation aids market over the forecast period. This is due to factors such as the growing understanding of e-cigarettes being safer than traditional cigarettes, increasing e-cigarette technologies like pod systems and squonk mods, and rising user adoption.
The use of e-cigarettes is increasing among the population, which is the key factor expected to drive the segment’s growth over the forecast period. For instance, according to the 2023 National Youth Tobacco Survey, published in November 2023, e-cigarettes continued to be the preferred tobacco product among youths, with 25.2% of middle and high school students who used them using them daily. Additionally, a significant 89.4% of students favored flavored e-cigarettes, and 25.2% used an e-cigarette daily.
According to data published by the CDC, in November 2023, about 1 out of every 22 middle school students (4.6%) reported that they had used electronic cigarettes in the past 30 days in 2023, which included 10.0% of high school students and 4.6% of middle school students. In addition, as per the same source, about 85% of those youth used flavored e-cigarettes and more than half used disposable e-cigarettes. The population's widespread adoption of e-cigarettes has boosted demand in the market. This has prompted companies to intensify their focus on innovation, propelling further growth in the segment.
Additionally, as per an article published in Tobacco Induced Diseases in October 2022, e-cigarettes were found to be superior to nicotine replacement therapy (NRT) in terms of a 7-day point abstinence rate and abstinence rate for more than six months continuously. Such factors are expected to increase the adoption of e-cigarettes among the population, propelling the segment's growth.
Furthermore, rising product launches by key players increase the availability of innovative smoking products and devices in the market, which is expected to boost the segment’s growth over the forecast period. For instance, in August 2022, SMOK launched a new SOLUS 2 Series, an upgraded version of the SOLUS series of Vaping Devices, at a global product launch event in Jakarta. It claims to provide an improved vaping experience and cost-effectiveness for vapers.
Similarly, in May 2022, Innokin Technology launched a lineup of vaporizers with water-based vaping technology with water-based juice, AQ30. Water-based vaping delivers smoother vapor and faster satisfaction than traditional vaping systems and reduces the dehydrating qualities of vapor.
Therefore, owing to the factors mentioned above, such as the high adoption of e-cigarettes and increasing product launches, the segment studied is expected to grow over the forecast period.
North America Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to witness significant growth in the market over the forecast period owing to factors such as the increasing burden of diseases associated with smoking, the growing number of favorable government initiatives, the increasing adoption of e-cigarettes and heated tobacco, and rising product launches.
The increasing adoption of e-cigarettes among the population is the key factor driving market growth. For instance, according to Statistics Canada, in October 2023, the total number of cigarettes sold increased by 15.5% to 1.2 billion from September 2023. Similarly, according to data published by the Government of Canada in March 2024, 12% of Canadians aged 25 and above reported current smoking, a significantly higher figure than the 4% reported by those aged 15-19. Smoking was more prevalent among men than women, with 13% of men reporting that they currently smoked compared with 9% of women. Hence, as cigarette consumption rises, the demand for smoking cessation aids is poised to surge, bolstering market growth.
Additionally, governments and private organizations in regional countries are creating awareness about nicotine patches and their benefits in quitting smoking, contributing to market growth. For instance, as per the Food and Drug Administration in July 2022, the smoking cessation products approved by the agency assist users in quitting and may even increase their success rates. In addition, over-the-counter nicotine replacement therapies (NRTs), including skin patches and transdermal nicotine patches, are approved for sale to people aged 18 and older.
Furthermore, increasing regional product launches and approvals are also contributing to market growth. For instance, in January 2024, Lupin Limited introduced Varenicline Tablets in 0.5 mg and 1 mg variants following approval from the United States Food and Drug Administration (FDA). These tablets, serving as the generic alternative to PF Prism CV's Chantix Tablets, are specifically designed to assist in smoking cessation.
Similarly, in May 2023, Perrigo Company PLC received final approval from the United States Food and Drug Administration for nicotine-coated mint lozenges, 2 mg and 4 mg over-the-counter (OTC). These lozenges help reduce withdrawal symptoms in consumers who are trying to quit smoking. Moreover, in September 2022, 22nd Century Group launched VLN, a low-nicotine cigarette in Colorado.
Therefore, the market studied is expected to grow over the forecast period due to the factors mentioned above, including the high adoption of smoking cessation products, increasing product launches and approvals, and growing government initiatives.
Smoking Cessation Aids Industry Overview
The smoking cessation aids market is fragmented due to the presence of small and large key players. Market players adopt several strategies, such as product launches, acquisitions, and mergers, to retain their market position. Also, the growing government initiatives to promote smoking cessation drugs and devices are further anticipated to propel market growth over the forecast period. Some of the key companies in the market are Pfizer Inc., NJOY, Johnson and Johnson, Takeda Pharmaceuticals Co. Ltd, Cipla Ltd, and GSK PLC.
Smoking Cessation Aids Market Leaders
-
Johnson and Johnson
-
Takeda Pharmaceuticals Co. Ltd.
-
NJOY
-
Pfizer Inc.
-
Cipla Ltd.
*Disclaimer: Major Players sorted in no particular order
Smoking Cessation Aids Market News
- June 2024: Ayrton Saunders Limited (Ayrtons), United Kingdom, received the UK Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval for its patented nicotine inhaler system to help smokers quit smoking. Also, the company stated that it has been actively seeking partners for the commercial launch of this novel nicotine-replacement therapy (NRT) in the United Kingdom and other key markets, setting the stage for a significant global impact.
- March 2024: Cigtrus launched Ezfly, a new range of transportation security administration (TSA)-accepted non-electric smokeless inhalers, at IAADFS’ Summit of the Americas. Ezfly provides a safe and effective solution, allowing travelers to enjoy their journey without compromising their well-being or the comfort of others.
- January 2024: Consilient Health reported that Cytisine would be available as a prescription-only stop-smoking medication.
Smoking Cessation Aids Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Large Population Addicted to Smoking
- 4.2.2 Awareness of the Hazards of Smoking
- 4.2.3 Banning Advertisements of Tobacco Products
-
4.3 Market Restraints
- 4.3.1 Adverse Effects of Drugs
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 Product
- 5.1.1 Nicotine Replacement Therapy
- 5.1.1.1 NRT Gum
- 5.1.1.2 NRT Lozenges
- 5.1.1.3 NRT Inhalers
- 5.1.1.4 NRT Patches
- 5.1.1.5 Sprays
- 5.1.2 Drugs
- 5.1.3 Electronic Cigarettes
- 5.1.4 Other Products
-
5.2 End User
- 5.2.1 Hospital Pharmacies
- 5.2.2 Online Channels
- 5.2.3 Retail Pharmacies
- 5.2.4 Other End Users
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 NJOY
- 6.1.2 Pfizer Inc.
- 6.1.3 GSK PLC
- 6.1.4 F. Hoffmann-La Roche AG
- 6.1.5 Novartis AG
- 6.1.6 Johnson and Johnson Inc.
- 6.1.7 Bayer AG
- 6.1.8 Cipla Ltd
- 6.1.9 Takeda Pharmaceuticals Co. Ltd
- 6.1.10 British American Tobacco PLC
- 6.1.11 22nd Century Group Inc.
- 6.1.12 Imperial Brands PLC
- 6.1.13 Dr. Reddy's Laboratories Ltd
- 6.1.14 Perrigo Company PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablitySmoking Cessation Aids Industry Segmentation
As per the scope of the report, tobacco use can lead to tobacco/nicotine dependence and serious health problems. Quitting smoking reduces greatly the risk of developing smoking-related diseases. Tobacco/nicotine dependence is a condition that often requires repeated treatment, but there are helpful treatments and resources for quitting. Tobacco smoke contains a deadly mix of more than 7,000 chemicals, of which hundreds are harmful, and about 70 can cause cancer.
The smoking cessation aids market is segmented by product, end user, and geography. By product, the market is segmented into nicotine replacement therapy, drugs, electronic cigarettes, and other products. By end user, the market is segmented into hospital pharmacies, online channels, retail pharmacies, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market sizes and forecasts in value (USD) for the above segments.
| Product | Nicotine Replacement Therapy | NRT Gum |
| NRT Lozenges | ||
| NRT Inhalers | ||
| NRT Patches | ||
| Sprays | ||
| Product | Drugs | |
| Electronic Cigarettes | ||
| Other Products | ||
| End User | Hospital Pharmacies | |
| Online Channels | ||
| Retail Pharmacies | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Smoking Cessation Aids Market Research FAQs
How big is the Smoking Cessation Aids Market?
The Smoking Cessation Aids Market size is expected to reach USD 32.60 billion in 2024 and grow at a CAGR of 11.37% to reach USD 55.84 billion by 2029.
What is the current Smoking Cessation Aids Market size?
In 2024, the Smoking Cessation Aids Market size is expected to reach USD 32.60 billion.
Who are the key players in Smoking Cessation Aids Market?
Johnson and Johnson, Takeda Pharmaceuticals Co. Ltd., NJOY, Pfizer Inc. and Cipla Ltd. are the major companies operating in the Smoking Cessation Aids Market.
Which is the fastest growing region in Smoking Cessation Aids Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Smoking Cessation Aids Market?
In 2024, the North America accounts for the largest market share in Smoking Cessation Aids Market.
What years does this Smoking Cessation Aids Market cover, and what was the market size in 2023?
In 2023, the Smoking Cessation Aids Market size was estimated at USD 28.89 billion. The report covers the Smoking Cessation Aids Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Smoking Cessation Aids Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Smoking Cessation Aids Industry Report
Statistics for the 2024 Smoking Cessation Aids market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Smoking Cessation Aids analysis includes a market forecast outlook to for 2024 to 2029) and historical overview. Get a sample of this industry analysis as a free report PDF download.
